

Save

Email

Send to

Display options

Comparative Study > J Autoimmun. 2021 Aug;122:102681. doi: 10.1016/j.jaut.2021.102681.

Epub 2021 Jun 15.

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Jimin Hwang ¹, Se Bee Lee ², Seung Won Lee ³, Min Ho Lee ⁴, Ai Koyanagi ⁵, Louis Jacob ⁶, Kalthoum Tizaoui ⁷, Dong Keon Yon ⁸, Jae Il Shin ⁹, Lee Smith ¹⁰

Affiliations + expand

PMID: 34139631 PMCID: PMC8204660 DOI: 10.1016/j.jaut.2021.102681

Free PMC article

Abstract

Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.


Keywords: Adenoviral vector vaccine; COVID-19 vaccine; Cerebral venous thrombosis; Thrombotic thrombocytopenia syndrome; Vaccine-induced thrombotic thrombocytopenia.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Conflict of interest statement

None.

Figures



FULL TEXT LINKS



ACTIONS

Cite

Favorites

SHARE



PAGE NAVIGATION

Title & authors

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources